155 related articles for article (PubMed ID: 35500243)
1. Design and Synthesis of Dual EZH2/BRD4 Inhibitors to Target Solid Tumors.
Guo Z; Sun Y; Liang L; Lu W; Luo B; Wu Z; Huo B; Hu Y; Huang P; Wu Q; Wen S
J Med Chem; 2022 May; 65(9):6573-6592. PubMed ID: 35500243
[TBL] [Abstract][Full Text] [Related]
2. Design, Synthesis, and Biological Evaluation of a Potent Dual EZH2-BRD4 Inhibitor for the Treatment of Some Solid Tumors.
Huang N; Liao P; Zuo Y; Zhang L; Jiang R
J Med Chem; 2023 Feb; 66(4):2646-2662. PubMed ID: 36774555
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and mechanism studies of dual EZH2/BRD4 inhibitors for cancer therapy.
Chen X; Wang C; Lu D; Luo H; Li S; Yin F; Luo Z; Cui N; Kong L; Wang X
Bioorg Med Chem; 2023 Aug; 91():117386. PubMed ID: 37379621
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors.
Ishi Y; Zhang Y; Zhang A; Sasaki T; Piunti A; Suri A; Watanabe J; Abe K; He X; Katagi H; Bhalla P; Natsumeda M; Zou L; Shilatifard A; Hashizume R
Mol Cancer Ther; 2022 May; 21(5):715-726. PubMed ID: 35247919
[TBL] [Abstract][Full Text] [Related]
5. Recent advances in EZH2-based dual inhibitors in the treatment of cancers.
Yang X; Xu L; Yang L
Eur J Med Chem; 2023 Aug; 256():115461. PubMed ID: 37156182
[TBL] [Abstract][Full Text] [Related]
6. Targeting Epigenetic Crosstalk as a Therapeutic Strategy for EZH2-Aberrant Solid Tumors.
Huang X; Yan J; Zhang M; Wang Y; Chen Y; Fu X; Wei R; Zheng XL; Liu Z; Zhang X; Yang H; Hao B; Shen YY; Su Y; Cong X; Huang M; Tan M; Ding J; Geng M
Cell; 2018 Sep; 175(1):186-199.e19. PubMed ID: 30220457
[TBL] [Abstract][Full Text] [Related]
7. EZH2 Cooperates with BRD4-NUT to Drive NUT Carcinoma Growth by Silencing Key Tumor Suppressor Genes.
Huang Y; Durall RT; Luong NM; Hertzler HJ; Huang J; Gokhale PC; Leeper BA; Persky NS; Root DE; Anekal PV; Montero Llopis PDLM; David CN; Kutok JL; Raimondi A; Saluja K; Luo J; Zahnow CA; Adane B; Stegmaier K; Hawkins CE; Ponne C; Le Q; Shapiro GI; Lemieux ME; Eagen KP; French CA
Cancer Res; 2023 Dec; 83(23):3956-3973. PubMed ID: 37747726
[TBL] [Abstract][Full Text] [Related]
8. Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds.
Fioravanti R; Stazi G; Zwergel C; Valente S; Mai A
Chem Rec; 2018 Dec; 18(12):1818-1832. PubMed ID: 30338896
[TBL] [Abstract][Full Text] [Related]
9. BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer.
Wu X; Liu D; Tao D; Xiang W; Xiao X; Wang M; Wang L; Luo G; Li Y; Zeng F; Jiang G
Mol Cancer Ther; 2016 May; 15(5):1029-42. PubMed ID: 26939702
[TBL] [Abstract][Full Text] [Related]
10. Expression and inhibition of BRD4, EZH2 and TOP2A in neurofibromas and malignant peripheral nerve sheath tumors.
Amirnasr A; Verdijk RM; van Kuijk PF; Taal W; Sleijfer S; Wiemer EAC
PLoS One; 2017; 12(8):e0183155. PubMed ID: 28813519
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Dual Lysine Methyltransferase G9a and EZH2 Inhibitors with In Vivo Efficacy against Malignant Rhabdoid Tumor.
Shi Y; Zhang Q; Zhang M; Chen Y; Sun J; Chen L; Liu S; Liu Z; Yang J; Wu C; Zheng Z; Wang L; Chen G
J Med Chem; 2023 Apr; 66(8):5685-5702. PubMed ID: 37021456
[TBL] [Abstract][Full Text] [Related]
12. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo.
Hu S; Yu L; Li Z; Shen Y; Wang J; Cai J; Xiao L; Wang Z
Cancer Biol Ther; 2010 Oct; 10(8):788-95. PubMed ID: 20686362
[TBL] [Abstract][Full Text] [Related]
14. Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effects.
Huang R; Wu Y; Zou Z
Epigenomics; 2022 Nov; 14(22):1449-1464. PubMed ID: 36601794
[TBL] [Abstract][Full Text] [Related]
15. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
16. Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2:
Chan-Penebre E; Armstrong K; Drew A; Grassian AR; Feldman I; Knutson SK; Kuplast-Barr K; Roche M; Campbell J; Ho P; Copeland RA; Chesworth R; Smith JJ; Keilhack H; Ribich SA
Mol Cancer Ther; 2017 May; 16(5):850-860. PubMed ID: 28292935
[TBL] [Abstract][Full Text] [Related]
17. Targeting Enhancer of Zeste Homolog 2 for the Treatment of Hematological Malignancies and Solid Tumors: Candidate Structure-Activity Relationships Insights and Evolution Prospects.
Xia J; Li J; Tian L; Ren X; Liu C; Liang C
J Med Chem; 2022 May; 65(10):7016-7043. PubMed ID: 35531606
[TBL] [Abstract][Full Text] [Related]
18. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
19. Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies.
Lu D; Wang C; Qu L; Yin F; Li S; Luo H; Zhang Y; Liu X; Chen X; Luo Z; Cui N; Kong L; Wang X
J Med Chem; 2022 Oct; 65(19):12838-12859. PubMed ID: 36153841
[TBL] [Abstract][Full Text] [Related]
20. The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing.
Nuytten M; Beke L; Van Eynde A; Ceulemans H; Beullens M; Van Hummelen P; Fuks F; Bollen M
Oncogene; 2008 Feb; 27(10):1449-60. PubMed ID: 17724462
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]